Unveiling the Rare: Pericardial and Peritoneal Mesothelioma

ByHolly Zink
Unveiling the Rare: Pericardial and Peritoneal Mesothelioma

Mesotheliomas are a rare type of cancer caused by exposure to asbestos. Mesothelioma in the lungs is called pleural mesothelioma and is the most common type. However, pericardial and peritoneal mesothelioma are even rarer forms.

These types of mesothelioma grow in the heart and in the abdomen. A team of researchers from the United States wanted to learn more. They looked at patients who were hospitalized with these unusual types of cancer.

Patients of Uncommon Mesothelioma Types

They ran a study looking at patients with pericardial and peritoneal mesothelioma who went to the hospital from 2016 to 2020. They split the patients into two groups. First, those with pericardial mesothelioma. And second, those with peritoneal mesothelioma.

The researchers looked at many factors. These were the patient’s age, how long they stayed in the hospital, how much it cost, and whether they had other health problems. They studied over 1,000 patients who fit their criteria. Out of those, 1,005 had peritoneal mesothelioma, and 100 had pericardial mesothelioma.

Most affected patients were older, with an average age of 62.8 years. More men than women were diagnosed with both types of mesothelioma, but pericardial mesothelioma had a bit more men (75% men and 25% women). In both groups, most patients were White (75%). There were fewer Hispanic, Black, and Asian/Pacific Islander patients.

Nearly all patients had other health problems in addition to mesothelioma. Managing multiple health problems was more common in patients with peritoneal mesothelioma. High blood pressure, diabetes, and chronic lung problems were the most common other health problems in both groups.

Most patients were treated in big teaching hospitals in urban areas. These types of hospitals have special tools and experts to help with complex diseases like mesothelioma. On average, patients stayed in the hospital for almost eight days. Interestingly, patients with pericardial mesothelioma had higher hospital stay costs than those with peritoneal mesothelioma.

From their study, the researchers learned that pericardial and peritoneal mesothelioma are more likely to affect older Caucasian men. These patients often have other health problems, which makes their care more complex.

This study helps shed light on pericardial and peritoneal mesothelioma, but there’s still much to learn. More research is needed to uncover the reasons behind the patterns that the researchers observed. This knowledge will be important in developing better ways to diagnose and treat all types of mesothelioma.

Source

Guevara N, Francis-Morel G, Perez E, Gupta S. Peritoneal and pericardial mesothelioma: A nationwide cross-sectional study. Chest. 2023;164(4):A1740. doi: 10.1016/j.chest.2023.07.1198. https://journal.chestnet.org/article/S0012-3692(23)02236-5/fulltext

Similar Posts

  • |

    New Prognostic Factor in Peritoneal Mesothelioma

    ByAlex Strauss

    Malignant peritoneal mesothelioma is a rare form of mesothelioma that attacks the membrane that lines the abdomen and surrounds internal organs. The outlook for this rare malignancy, which affects fewer than 500 Americans annually, has been improved by the treatment combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The combination has produced 5-year overall survival rates ranging from 29% to 63%. But not all peritoneal mesothelioma patients are good candidates for CRS/HIPEC. The challenge, for clinicians, is identifying which patients are likely to benefit from the procedure (or even be cured) and which are not. In an effort to help answer that question, French researchers recently tested the prognostic value of the glucose transporter protein GLUT1 as well as…

  • |

    Study Lists Factors That Impact Mesothelioma Prognosis

    ByAlex Strauss

    Predicting survival in mesothelioma patients does not have to be complicated. A new Parisian study suggests that simple-to-measure factors such as patient age and the histological subtype of the mesothelioma can be highly accurate prognostic indicators. The study followed 170 patients diagnosed with malignant pleural mesothelioma between 2000 and 2010 at Saint Antoine Hospital in Paris. Patients in the study were all treated non-surgically. For each patient, a list of parameters was recorded including age, gender, tobacco use, asbestos exposure, type and duration of symptoms, BMI, C-reactive protein levels and white blood cell and platelet counts.  Inflammation of the pleura (pachypleuritis) was also noted, along with the type of diagnostic surgical procedure, histological subtype, the way in which pleurodesis was performed (for…

  • |

    Predicting Mesothelioma Outcomes with Blood Tests

    ByAlex Strauss

    Two separate teams of Japanese researchers are delving into the possibilities of blood serum indicators that could help predict outcomes in patients with malignant pleural mesothelioma. Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. Pleural mesothelioma, a cancer that starts on the lining around the lungs, is the most common form of the disease. It occurs most often in people who have inadvertently inhaled asbestos dust. Mesothelioma is highly resistant to conventional treatments. It is also difficult to predict which patients are likely to do well with standard therapies and which are not, which is referred to as prognosis. But researchers worldwide are continually searching for new ways to diagnose and predict the prognosis of patients with…

  • |

    Drop in Lung Volume Predicts Poor Mesothelioma Outcome

    ByAlex Strauss

    Decreases in lung volume may be an indicator of treatment response for patients with mesothelioma. Researchers in the U.S. and Australia reached that conclusion after studying the cases of 61 patients with malignant pleural mesothelioma and 216 CT scans taken of them during the course of their standard chemotherapy treatment. Lung volume is a measurement of the amount of air the lung processes (inhales, exhales and holds on to) during the course of a normal breath. People with malignant pleural mesothelioma, a cancer that starts on the lining around the lungs, typically experience a drop in lung volume as the pleural tumor grows and constricts or even invades one of their lungs. The new study measured changes in each mesothelioma patient’s…

  • | |

    Systemic Chemotherapy Ineffective in Peritoneal Mesothelioma?

    ByAlex Strauss

    Peritoneal mesothelioma is a rare cancer that occurs in the membranous lining of the abdomen. This virulent cancer is caused by exposure to asbestos. Because it is so aggressive, most patients with peritoneal mesothelioma are treated with multiple modalities, or a variety of different treatments, in an effort to attack the cancer from all sides. For patients whose mesothelioma is considered operable, surgery is frequently preceded by a round of preoperative chemotherapy. Also referred to as neoadjuvant chemotherapy, preoperative chemotherapy aims to shrink the tumor as much as possible before cytoreductive surgery. Later, during surgery, the same peritoneal mesothelioma patient may have intraoperative chemotherapy (HIPEC) in which chemotherapy drugs are washed through the body cavity where the cancer was found. The procedure…

  • |

    New Prognostic Tools Could Improve Mesothelioma Treatment

    ByAlex Strauss

    A pair of cancer researchers from Rome say treatment for malignant pleural mesothelioma could be improved if more clinicians considered the newest prognostic tools in their treatment planning. Pleural mesothelioma is a malignancy of the membranes that encase the lungs. It is caused by exposure to the mineral asbestos and is highly resistant to conventional cancer therapies. Many mesothelioma patients do not survive longer than 12 months from the onset of their symptoms. But Tommaso Mineo, MD, and Vincenzo Ambrogi, PhD, of the Department of Experimental Medicine and Surgery at Policlinico Tor Vergata University say newly discovered biomarkers and other tumor factors could lead to more tailored treatment and, potentially, better outcomes. “Therapy is currently guided by gross tumor characteristics and patient…